Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: An example from the Canadian Cancer Trials Group CO.17 trial

Jeffrey S Hoch, Annette Hay, Wanrudee Isaranuwatchai, Kednapa Thavorn, Natasha B. Leighl, Dongsheng Tu, Logan Trenaman, Carolyn S Dewa, Chris O'Callaghan, Joseph Pater, Derek Jonker, Bingshu E. Chen, Nicole Mittmann

Research output: Contribution to journalArticle

Abstract

Background: Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated. Methods: To illustrate regression-based economic evaluation, we review a cost-effectiveness analysis conducted by the Canadian Cancer Trials Group's Committee on Economic Analysis and implement net benefit regression. Results: Net benefit regression offers a simple option for cost-effectiveness analyses of person-level data. By placing economic evaluation in a regression framework, regression-based techniques can facilitate the analysis and provide simple solutions to commonly encountered challenges (e.g., the need to adjust for potential confounders, identify key patient subgroups, and/or summarize "challenging" findings, like when a more effective regimen has the potential to be cost-saving). Conclusions: Economic evaluations of patient-level data (e.g., from a clinical trial) can use net benefit regression to facilitate analysis and enhance results.

Original languageEnglish (US)
Article number552
JournalBMC Cancer
Volume19
Issue number1
DOIs
StatePublished - Jun 7 2019
Externally publishedYes

Fingerprint

Cost-Benefit Analysis
Neoplasms
Therapeutics
Economics
Clinical Trials
Costs and Cost Analysis

Keywords

  • Cost-effectiveness
  • Economic evaluation
  • Net benefit regression

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments : An example from the Canadian Cancer Trials Group CO.17 trial. / Hoch, Jeffrey S; Hay, Annette; Isaranuwatchai, Wanrudee; Thavorn, Kednapa; Leighl, Natasha B.; Tu, Dongsheng; Trenaman, Logan; Dewa, Carolyn S; O'Callaghan, Chris; Pater, Joseph; Jonker, Derek; Chen, Bingshu E.; Mittmann, Nicole.

In: BMC Cancer, Vol. 19, No. 1, 552, 07.06.2019.

Research output: Contribution to journalArticle

Hoch, JS, Hay, A, Isaranuwatchai, W, Thavorn, K, Leighl, NB, Tu, D, Trenaman, L, Dewa, CS, O'Callaghan, C, Pater, J, Jonker, D, Chen, BE & Mittmann, N 2019, 'Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: An example from the Canadian Cancer Trials Group CO.17 trial', BMC Cancer, vol. 19, no. 1, 552. https://doi.org/10.1186/s12885-019-5779-x
Hoch, Jeffrey S ; Hay, Annette ; Isaranuwatchai, Wanrudee ; Thavorn, Kednapa ; Leighl, Natasha B. ; Tu, Dongsheng ; Trenaman, Logan ; Dewa, Carolyn S ; O'Callaghan, Chris ; Pater, Joseph ; Jonker, Derek ; Chen, Bingshu E. ; Mittmann, Nicole. / Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments : An example from the Canadian Cancer Trials Group CO.17 trial. In: BMC Cancer. 2019 ; Vol. 19, No. 1.
@article{c627889117564089a7d9bd2b29ebdadb,
title = "Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: An example from the Canadian Cancer Trials Group CO.17 trial",
abstract = "Background: Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated. Methods: To illustrate regression-based economic evaluation, we review a cost-effectiveness analysis conducted by the Canadian Cancer Trials Group's Committee on Economic Analysis and implement net benefit regression. Results: Net benefit regression offers a simple option for cost-effectiveness analyses of person-level data. By placing economic evaluation in a regression framework, regression-based techniques can facilitate the analysis and provide simple solutions to commonly encountered challenges (e.g., the need to adjust for potential confounders, identify key patient subgroups, and/or summarize {"}challenging{"} findings, like when a more effective regimen has the potential to be cost-saving). Conclusions: Economic evaluations of patient-level data (e.g., from a clinical trial) can use net benefit regression to facilitate analysis and enhance results.",
keywords = "Cost-effectiveness, Economic evaluation, Net benefit regression",
author = "Hoch, {Jeffrey S} and Annette Hay and Wanrudee Isaranuwatchai and Kednapa Thavorn and Leighl, {Natasha B.} and Dongsheng Tu and Logan Trenaman and Dewa, {Carolyn S} and Chris O'Callaghan and Joseph Pater and Derek Jonker and Chen, {Bingshu E.} and Nicole Mittmann",
year = "2019",
month = "6",
day = "7",
doi = "10.1186/s12885-019-5779-x",
language = "English (US)",
volume = "19",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments

T2 - An example from the Canadian Cancer Trials Group CO.17 trial

AU - Hoch, Jeffrey S

AU - Hay, Annette

AU - Isaranuwatchai, Wanrudee

AU - Thavorn, Kednapa

AU - Leighl, Natasha B.

AU - Tu, Dongsheng

AU - Trenaman, Logan

AU - Dewa, Carolyn S

AU - O'Callaghan, Chris

AU - Pater, Joseph

AU - Jonker, Derek

AU - Chen, Bingshu E.

AU - Mittmann, Nicole

PY - 2019/6/7

Y1 - 2019/6/7

N2 - Background: Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated. Methods: To illustrate regression-based economic evaluation, we review a cost-effectiveness analysis conducted by the Canadian Cancer Trials Group's Committee on Economic Analysis and implement net benefit regression. Results: Net benefit regression offers a simple option for cost-effectiveness analyses of person-level data. By placing economic evaluation in a regression framework, regression-based techniques can facilitate the analysis and provide simple solutions to commonly encountered challenges (e.g., the need to adjust for potential confounders, identify key patient subgroups, and/or summarize "challenging" findings, like when a more effective regimen has the potential to be cost-saving). Conclusions: Economic evaluations of patient-level data (e.g., from a clinical trial) can use net benefit regression to facilitate analysis and enhance results.

AB - Background: Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated. Methods: To illustrate regression-based economic evaluation, we review a cost-effectiveness analysis conducted by the Canadian Cancer Trials Group's Committee on Economic Analysis and implement net benefit regression. Results: Net benefit regression offers a simple option for cost-effectiveness analyses of person-level data. By placing economic evaluation in a regression framework, regression-based techniques can facilitate the analysis and provide simple solutions to commonly encountered challenges (e.g., the need to adjust for potential confounders, identify key patient subgroups, and/or summarize "challenging" findings, like when a more effective regimen has the potential to be cost-saving). Conclusions: Economic evaluations of patient-level data (e.g., from a clinical trial) can use net benefit regression to facilitate analysis and enhance results.

KW - Cost-effectiveness

KW - Economic evaluation

KW - Net benefit regression

UR - http://www.scopus.com/inward/record.url?scp=85066861264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066861264&partnerID=8YFLogxK

U2 - 10.1186/s12885-019-5779-x

DO - 10.1186/s12885-019-5779-x

M3 - Article

C2 - 31174497

AN - SCOPUS:85066861264

VL - 19

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 552

ER -